Show simple item record

Subcutaneous epcoritamab with rituximab plus lenalidomide (R-2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial

dc.contributor.authorFalchi, L.
dc.contributor.authorLeppa, S.
dc.contributor.authorWahlin, B. E.
dc.contributor.authorNijland, M.
dc.contributor.authorChristensen, J. H.
dc.contributor.authorDe Vos, S.
dc.contributor.authorHolte, H.
dc.contributor.authorLinton, Kim M
dc.contributor.authorAbbas, A.
dc.contributor.authorWang, L. W.
dc.contributor.authorDinh, M.
dc.contributor.authorElliott, B.
dc.contributor.authorBelada, D.
dc.date.accessioned2022-11-30T10:21:28Z
dc.date.available2022-11-30T10:21:28Z
dc.date.issued2022en
dc.identifier.citationFalchi L, Leppa S, Wahlin BE, Nijland M, Christensen JH, De Vos S, et al. Subcutaneous epcoritamab with rituximab plus lenalidomide (R-2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301985.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.7524en
dc.identifier.urihttp://hdl.handle.net/10541/625816
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.7524en
dc.titleSubcutaneous epcoritamab with rituximab plus lenalidomide (R-2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentLymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY;en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record